Q1 2023 EPS Estimates for Altimmune, Inc. (NASDAQ:ALT) Lifted by Analyst

Altimmune, Inc. (NASDAQ:ALT – Get Rating) – HC Wainwright raised their Q1 2023 earnings estimates for shares of Altimmune in a research report issued to clients and investors on Thursday, March 9th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.48) per share for the quarter, up from their previous forecast of ($0.49). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.94) per share. HC Wainwright also issued estimates for Altimmune’s Q2 2023 earnings at ($0.48) EPS, Q3 2023 earnings at ($0.52) EPS, Q4 2023 earnings at ($0.48) EPS, FY2023 earnings at ($1.97) EPS, FY2024 earnings at ($1.95) EPS, FY2025 earnings at ($1.79) EPS, FY2026 earnings at ($1.17) EPS and FY2027 earnings at $0.29 EPS.

Altimmune (NASDAQ:ALT – Get Rating) last announced its quarterly earnings data on Tuesday, February 28th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.09. Altimmune had a negative net margin of 2,618.74% and a negative return on equity of 44.02%. The company had revenue of ($0.11) million for the quarter, compared to the consensus estimate of $0.11 million.

Several other equities analysts also recently weighed in on the stock. Evercore ISI raised their target price on shares of Altimmune from $14.00 to $25.00 and gave the company an “outperform” rating in a report on Wednesday, January 18th. The Goldman Sachs Group started coverage on shares of Altimmune in a research note on Thursday, December 1st. They set a “buy” rating and a $20.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Altimmune has a consensus rating of “Buy” and an average price target of $29.13.

Altimmune Stock Performance

ALT stock opened at $10.37 on Monday. Altimmune has a one year low of $3.83 and a one year high of $23.49. The stock has a market capitalization of $511.03 million, a PE ratio of -5.86 and a beta of 0.11. The company has a fifty day moving average of $13.52 and a 200-day moving average of $13.13.

Institutional Trading of Altimmune

A number of large investors have recently bought and sold shares of ALT. Graham Capital Management L.P. purchased a new stake in Altimmune during the first quarter valued at about $63,000. Engineers Gate Manager LP purchased a new position in Altimmune in the 1st quarter worth approximately $87,000. Dynamic Technology Lab Private Ltd purchased a new stake in Altimmune during the 1st quarter valued at $106,000. King Wealth purchased a new stake in shares of Altimmune in the 2nd quarter worth $117,000. Finally, XTX Topco Ltd increased its stake in shares of Altimmune by 33.2% in the 1st quarter. XTX Topco Ltd now owns 19,665 shares of the company’s stock worth $120,000 after purchasing an additional 4,898 shares in the last quarter. 93.69% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Altimmune

In other news, Director Wayne Pisano sold 20,000 shares of Altimmune stock in a transaction that occurred on Thursday, December 22nd. The stock was sold at an average price of $15.01, for a total transaction of $300,200.00. Following the completion of the transaction, the director now directly owns 8,498 shares in the company, valued at approximately $127,554.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.19% of the stock is currently owned by insiders.

About Altimmune

(Get Rating)

Altimmune, Inc is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.